drugset / Trial / NCT06111352

Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime

NCT06111352

Phase 2 Completed 96 enrolled Sir Salimullah Medical College Mitford Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This open level randomized controlled trial will be conducted in the department of medicine at Sir Salimullah Medical College and Mitford Hospital. Clinical severity will be assessed by the POP (Peradeniya Organophosphorus Poisoning) scale of admitted patients having a history of organophosphorus poisoning within 24 hours with clinical features and physical evidence of poisoning consumed. Only moderate severity (POP Scale score 4-7) of OPC (Organophosphorus compound) patients will be included in this study. Then one group of patients will be treated with atropine and pralidoxime and another group will be treated with atropine. The outcome will be noted as clinical improvement or recovery. hospital stay, requirement of ICU, death.

Timeline

Start
2022-06-01
Primary completion
2023-09-30
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pralidoxime Small molecule 1 g Intravenous
Background Atropine Other / unclassified 1.8 mg Intravenous